source
- FDA peptide panel faces clash as Ebola outbreak kills over 1,000 and vaccine options remain limitedThe FDA is holding a two‑day panel on peptide therapeutics, and observers anticipate heated debate among regulators and industry. The African CDC reports the fastest‑growing Ebola outbreak, with m…
- Roche halts lupus T-cell engager RG6382 development after early trial reviewRoche announced it is stopping work on RG6382, a bispecific T-cell engager targeting CD19 and CD3, which was being tested in a phase‑1 study in patients with systemic lupus erythematosus (SLE). Th…